Associations Between Drug Exposure and Outcomes in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2020 May;18(5):1244-1245. doi: 10.1016/j.cgh.2019.09.044. Epub 2019 Oct 5.

Authors

Brian M Fung¹, Ahmad H Ali², James H Tabibian³

Affiliations

¹ UCLA-Olive View Internal Medicine Residency Program, Sylmar, California.
² Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
³ Division of Gastroenterology, Olive View-UCLA Medical Center, Sylmar, California.

PMID: 31593771
DOI: 10.1016/j.cgh.2019.09.044

No abstract available

Publication types

Letter
Comment

MeSH terms

Cholangitis, Sclerosing*
Colitis*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Inflammatory Bowel Diseases* / drug therapy
Pharmaceutical Preparations*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmaceutical Preparations